Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Local Antioxidant Therapy and Racial Differences in Vasoconstriction
NCT03684213Phase 1Completed
- Sponsor
- The University of Texas at Arlington
- Start
- Oct 2018
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ascorbic acid in cardiovascular disease (CVD) (4 arms), sponsored by The University of Texas at Arlington. Primary endpoints: Vasoconstrictor Responsiveness to Norepinephrine and Role of Oxidative Stress in Heightened Vasoconstriction. Started Oct 2018; status: completed.
02
Drugs
ascorbic acid
03
Conditions
cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT03684213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03684213.